哪里想瘦打哪里！FDA批准Kythera施用药物上市在即

你才双下巴，你全家都双下巴！乃是小姑娘决意人皆有之。如果说赘肉是每一个希望具备完美体格的“妹纸”或“汉纸”的大敌，那么一个喜感十足的双下巴无疑是这些人的生死罪人了。每一分钟，全世界都有人为自己的一张大饼脸而感到执著，虽然具备一个肉感十足的双下巴钉上去是不下有肉感的，但是还是有很多人的协调性使其难以受压一个双下巴之重。您可千万别笑，这甚至已经催生出一个相当可观的产品。根据美国表皮外科手术理事会的核查研究课题显示，68%的加拿大人对自己的双下巴表示了“厌倦”之情。而有鉴于此，最近Kythera一些公司向FDA提交了其专供剿灭双下巴的化妆品注射式抗生素ATX-101。这种抗生素完成了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，无疑是区域内减肥。不要以为这种正因如此任性的抗生素只是一个笑话，在FDA下属的表皮和内科抗生素高级专员会的无记名投票中会，专家可是以17：0的超高票数完全一致赞同其主板。或许是因为这些专家中会也有很多饱受双下巴之苦吧。FDA也将蓝图于本年度的5同年13日之前对其作出最终要求。如果一切顺利的话，Kythera一些公司蓝图于本年度年初将该产品主板，分析部分人预估这一抗生素的产值将多达3亿美元之多。随着化妆品抗生素产品的愈发增大，Kythera一些公司无疑是下了一步好棋。一些公司于上次以8400万美元的价格从其前合作伙伴拜耳交给会转让了这种抗生素的全部权利。而Kythera一些公司也希望用意为契机在化妆品抗生素产品中会攻城拔寨。就在上个同年，Kythera一些公司和Actelion一些公司达成价值2700万美元的合作协议，共同合作开发一种失败过的抗发炎抗生素，而这种抗生素被相信有可能合作开发出一种疗程病变的抗生素。参考中文名路透社：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.